Cargando…

Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. A minority of affected patients develops inflammation, subsequently fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC is a leading cause o...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaele, Marco, Kovacovicova, Kristina, Frohlich, Jan, Lo Re, Oriana, Giallongo, Sebastiano, Oben, Jude A., Faldyna, Martin, Leva, Lenka, Giannone, Antonino Giulio, Cabibi, Daniela, Vinciguerra, Manlio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034117/
https://www.ncbi.nlm.nih.gov/pubmed/33832488
http://dx.doi.org/10.1186/s12964-021-00731-0
_version_ 1783676484892753920
author Raffaele, Marco
Kovacovicova, Kristina
Frohlich, Jan
Lo Re, Oriana
Giallongo, Sebastiano
Oben, Jude A.
Faldyna, Martin
Leva, Lenka
Giannone, Antonino Giulio
Cabibi, Daniela
Vinciguerra, Manlio
author_facet Raffaele, Marco
Kovacovicova, Kristina
Frohlich, Jan
Lo Re, Oriana
Giallongo, Sebastiano
Oben, Jude A.
Faldyna, Martin
Leva, Lenka
Giannone, Antonino Giulio
Cabibi, Daniela
Vinciguerra, Manlio
author_sort Raffaele, Marco
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. A minority of affected patients develops inflammation, subsequently fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related death. An increased number of senescent cells correlate with age-related tissue degeneration during NAFLD-induced HCC. Senolytics are promising agents that target selectively senescent cells. Previous studies showed that whereas a combination of the senolytic drugs dasatinib and quercetin (D + Q) reduced NAFLD in mice, D + Q lacked efficacy in removing doxorubicin-induced β-gal-positive senescent cells in human HCC xenografted mice. Whether D + Q has an effect on the age-associated spectrum of NAFLD-inflammation-HCC remains unknown. METHODS: Here, we utilized an established model of age- and obesity-associated HCC, the low dose diethylnitrosamine (DEN)/high fat diet (HFD), a regimen promoting liver inflammation and tumorigenesis over a long period of 9 months. Four groups of mice each were created: group 1 included control untreated mice; group 2 included mice treated with D + Q; group 3 included mice undergoing the DEN/HFD protocol; group 4 included mice undergoing the DEN/HFD protocol with the administration of D + Q. At the end of the chemical/dietary regimen, we analyzed liver damage and cell senescence by histopathology, qPCR and immunoblotting approaches. RESULTS: Unexpectedly, D + Q worsened liver disease progression in the DEN/HFD mouse model, slightly increasing histological damage and tumorigenesis, while having no effect on senescent cells removal. CONCLUSIONS: In summary, using an animal model that fully recapitulates NAFLD, we demonstrate that these compounds are ineffective against age-associated NAFLD-induced HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00731-0.
format Online
Article
Text
id pubmed-8034117
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80341172021-04-12 Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin Raffaele, Marco Kovacovicova, Kristina Frohlich, Jan Lo Re, Oriana Giallongo, Sebastiano Oben, Jude A. Faldyna, Martin Leva, Lenka Giannone, Antonino Giulio Cabibi, Daniela Vinciguerra, Manlio Cell Commun Signal Short Report BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing challenge in terms of prevention and treatment. A minority of affected patients develops inflammation, subsequently fibrosis, cirrhosis and hepatocellular carcinoma (HCC). HCC is a leading cause of cancer-related death. An increased number of senescent cells correlate with age-related tissue degeneration during NAFLD-induced HCC. Senolytics are promising agents that target selectively senescent cells. Previous studies showed that whereas a combination of the senolytic drugs dasatinib and quercetin (D + Q) reduced NAFLD in mice, D + Q lacked efficacy in removing doxorubicin-induced β-gal-positive senescent cells in human HCC xenografted mice. Whether D + Q has an effect on the age-associated spectrum of NAFLD-inflammation-HCC remains unknown. METHODS: Here, we utilized an established model of age- and obesity-associated HCC, the low dose diethylnitrosamine (DEN)/high fat diet (HFD), a regimen promoting liver inflammation and tumorigenesis over a long period of 9 months. Four groups of mice each were created: group 1 included control untreated mice; group 2 included mice treated with D + Q; group 3 included mice undergoing the DEN/HFD protocol; group 4 included mice undergoing the DEN/HFD protocol with the administration of D + Q. At the end of the chemical/dietary regimen, we analyzed liver damage and cell senescence by histopathology, qPCR and immunoblotting approaches. RESULTS: Unexpectedly, D + Q worsened liver disease progression in the DEN/HFD mouse model, slightly increasing histological damage and tumorigenesis, while having no effect on senescent cells removal. CONCLUSIONS: In summary, using an animal model that fully recapitulates NAFLD, we demonstrate that these compounds are ineffective against age-associated NAFLD-induced HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00731-0. BioMed Central 2021-04-08 /pmc/articles/PMC8034117/ /pubmed/33832488 http://dx.doi.org/10.1186/s12964-021-00731-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Raffaele, Marco
Kovacovicova, Kristina
Frohlich, Jan
Lo Re, Oriana
Giallongo, Sebastiano
Oben, Jude A.
Faldyna, Martin
Leva, Lenka
Giannone, Antonino Giulio
Cabibi, Daniela
Vinciguerra, Manlio
Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title_full Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title_fullStr Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title_full_unstemmed Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title_short Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
title_sort mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034117/
https://www.ncbi.nlm.nih.gov/pubmed/33832488
http://dx.doi.org/10.1186/s12964-021-00731-0
work_keys_str_mv AT raffaelemarco mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT kovacovicovakristina mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT frohlichjan mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT loreoriana mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT giallongosebastiano mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT obenjudea mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT faldynamartin mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT levalenka mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT giannoneantoninogiulio mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT cabibidaniela mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin
AT vinciguerramanlio mildexacerbationofobesityandagedependentliverdiseaseprogressionbysenolyticcocktaildasatinibquercetin